Perceiv AI is an AI-driven precision medicine company developing a powerful multimodal prognostic platform to forecast disease progression in age-related diseases like Alzheimer's. By providing a window into individual patients’ disease progression, Perceiv AI aims to accelerate and de-risk the development of new therapies while enabling timelier diagnoses. Perceiv provides a multimodal prognostic platform supporting imaging, genetic and clinical data to forecast disease progression.
What is the problem?
The uncertainty regarding disease progression leads to late diagnosis and an avoidable cost of $7T for Alzheimer's disease. It also contributes to the recruitment of a large proportion of individuals not suitable to demonstrate drug efficacy leading to large and long clinical trials that have a staggering failure rate of 99.6%. This represents an opportunity of over $9B to reduce the failure risk and size of these trials and make sure we treat and evaluate therapies on the right patient to provide the best outcome for them. The one size fits all model does not work in complex multifactorial diseases and a precision medicine approach is required.
What is their solution?
We want to go beyond diagnosis and provide a window into the future of patients currently inexistent in a lot of complex diseases like Alzheimer’s disease. Our platform currently predicts the individual patient risk of declining in its cognition in the next 2 years across the disease spectrum. This insight can be used to select the right individuals more likely to respond to treatment and can support physicians (in particular, primary care physicians who are currently under resourced) into timelier diagnoses.
